Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research focused on Mitoxantrone and Multiple myeloma, with related work in Bone marrow, Diffuse large B-cell lymphoma, Daratumumab. Notable publications include 'The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment', 'Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma', and 'SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial'.
764 | REAL‐WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR PERIPHERAL T‐CELL LYMPHOMA: THE EFFICACY AND SAFETY ANALYSIS OF TREATMENT‐NAÏVE POPULATION
Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study
The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment
SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial
Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma
Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis